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Peptoid efficacy against polymicrobial biofilms determined using 
propidium monoazide – modified quantitative PCR 
Yu Luo[a]#, Hannah L. Bolt[b]#, Gabriela A. Eggimann[b], Danny F. McAuley[a], Ronan McMullan[a], Tanya 
Curran[c], Mei Zhou[d], Colin A. B. Jahoda[e], Steven L. Cobb[b]* and Fionnuala T. Lundy[a]*  
 
Biofilms containing C. albicans are responsible for a wide 
variety of clinical infections. The protective effects of the 
biofilm matrix, the low metabolic activity of microorganisms 
within a biofilm and their high mutation rate, significantly 
enhance the resistance of biofilms to conventional 
antimicrobial treatments. Peptoids are peptide-mimics that 
share many features of host defence antimicrobial peptides, but 
have increased resistance to proteases and therefore better 
stability in vivo. The activity of a library of peptoids was tested 
against both monospecies and polymicrobial bacterial/fungal 
biofilms. Selected peptoids showed significant bactericidal and 
fungicidal activity against the polymicrobial biofilms. This 
coupled with low cytotoxicity, suggests that peptoids could 
offer a new option for the treatment of clinically relevant 
polymicrobial infections in the future. 
Introduction 
It is well recognised that clinically relevant micro-organisms exist 
naturally as complex biofilm communities which differ 
substantially from their planktonic counterparts.1,2 Biofilm 
organisms have a propensity for metabolic inactivity, and 
therefore antimicrobial agents showing promise in planktonic 
culture tend to be less efficacious against biofilms.1 The biofilm 
mode of growth has therefore been proposed as a mechanism 
for the resistance of many chronic infections to antimicrobial 
agents.3  
 
The majority of in vitro treatment studies on biofilms focus on 
single species biofilms, whereas it is recognised that biofilms in 
vivo are naturally polymicrobial, consisting of several species 
which may include members of both the bacterial and fungal 
genera.  In polymicrobial infections in vivo, micro-organisms 
have been proposed to influence each other either by exchange 
of molecules (sensing and signaling) or by physical contact 
(biofilm architecture) which may ultimately facilitate competitive, 
synergistic or neutral relationships.4,5 In addition to a growing 
interest in multispecies bacterial biofilms6 there is also an 
emerging interest in the study of polymicrobial fungal-bacterial 
biofilms.  Cross-kingdom biofilms containing Candida albicans7 
have been shown to be associated with clinical infections of both 
biotic and abiotic surfaces, ranging from the cornea8 to 
endotracheal tubes9 respectively.10 Although the role of C. 
albicans in polymicrobial biofilm formation is likely to be a 
complex one, recent works suggest that C. albicans dramatically 
modifies the physical environment and 3D architecture of 
polymicrobial biofilms11 as well as influencing interspecies 
protein expression12 and eDNA release.13 
 
Of particular concern in the current climate of antimicrobial 
resistance are the findings, from drug susceptibility studies, that 
fungal cells can modulate the action of antibiotics and that 
bacteria can influence antifungal activity.14 Given the importance 
of polymicrobial biofilms in vivo10 and the increased bacterial 
resistance to antibiotics observed in polymicrobial biofilms with 
C. albicans15, new treatments for cross-kingdom biofilms are 
urgently required. The efficacy of the innate immune system’s 
host defence peptides (HDPs) in providing the first line of 
defence against infection, and their broad spectrum action 
against both bacteria and fungi, has prompted our research 
group and others to investigate HDPs as templates for the 
design of innovative therapeutics.16-19 There is particular need to 
identify new strategies for managing infection that spare 
conventional systemic antimicrobial drugs. Despite promising in 
vitro antimicrobial activities against a range of bacterial and 
fungal pathogens, HDPs have been shown to be susceptible to 
degradation by proteinases at wound and inflammatory sites20,21, 
potentially limiting their application as anti-infectives in vivo. 
Despite the fact that the clinical success of such peptides has 
been somewhat limited22, continuing advances in the design of 
peptide mimics and the unmet clinical need for novel 
antimicrobials have reinvigorated this research field. 
 
Oligo N-substituted glycines (peptoids) are peptide analogs that 
combine many of the features of HDPs, with the added 
advantage that they are resistant to proteinases23 and therefore 
offer a new avenue for antimicrobial therapeutics. Peptoids are 
structural isomers of peptides, where the side-chain functionality 
is attached to the nitrogen atom of the amide backbone, rather 
than the α-carbon of a peptide sequence (see Figure 1).  
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Figure 1. Representative structure of an α-peptide and an α-peptoid. 
 
Peptoids have previously been shown to be efficacious against 
planktonic micro-organisms24,25 and against bacterial biofilms26 
but to date their activity against fungal biofilms and, in particular, 
polymicrobial bacterial-fungal biofilms remains to be determined.  
 
In this study we initially screened the efficacy of a linear peptoid 
library against C. albicans, Staphylococcus aureus and 
Escherichia coli monospecies biofilms and then determined 
selected peptoid efficacy against polymicrobial bacterial-fungal 
biofilms consisting of C. albicans – S. aureus or C. albicans – E. 
coli. We used a crystal violet assay for initial screening purposes 
and adapted a novel quantitative PCR (qPCR), approach 
employing propidium monoazide (PMA)27, for determining viable 
organism numbers within the polymicrobial biofilms. The PMA-
qPCR assay is highly advantageous over traditional colony 
forming unit (CFU) assays in that it allows quantification of viable 
but non-culturable (VBNC) micro-organisms. The PMA-qPCR 
assay is therefore particularly relevant for quantification of micro-
organism within biofilms, which by their very nature are likely to 
contain VBNC micro-organisms. Additionally, the crystal violet 
assay cannot distinguish between different species within a 
polymicrobial biofilm. However, qPCR can determine viable cell 
counts for individual specific pathogens within polymicrobial 
biofilms and therefore it offers a significant advantage in studies 
of this kind. To the best of our knowledge, this is also the first 
time that peptoids have been proven to be efficacious against 
fungal biofilms.  
Results and Discussion 
Peptoid design and synthesis 
 
To assess the anti-biofilm activity of peptoids, a library of 18 
linear peptoids was synthesized. The sequences were designed 
around a NxNyNy subunit (Table 1), repeated two, three or four 
times (6-, 9- and 12 residue peptoids respectively), where Nx is 
a positively charged lysine-type amine with various side chain 
lengths (Nah N-(6-aminohexyl) glycine, NLys N-(4-aminobutyl) 
glycine and Nae N-(2-aminoethyl) glycine) and Ny is either the 
chiral aromatic building block Nspe N-(S-phenylethyl) glycine or 
the achiral Nphe N-benzylglycine. Peptoids were synthesised 
with a repeat unit of three residues in order to induce an 
amphipathic structure and included the bulky Nphe and Nspe 
monomers as these are reported to encourage a helical 
structure that can lead to an improved antimicrobial effect. 28-31 
The 18 peptoids were classified into 3 families (peptoids 1-6; 
peptoids 7-12 and peptoids 13-18) based on their positively 
charged building blocks (Nah, NLys or Nae). All peptoids were 
synthesised manually on resin using the sub-monomer method32 
using a shaker platform at room temperature (acylation steps 15 
mins and displacement steps 15 mins). The library was purified 
using RP-HPLC to >95% purity (see Supplementary Material for 
peptoid synthesis and characterisation).  
 
Peptoid efficacy against single species biofilms 
 
For initial screening purposes, the entire peptoid library was 
tested against single species biofilms of C. albicans, S. aureus 
and E. coli, using a crystal violet assay (Figure 2).  
Figure 2. Efficacy of a family of 18 peptoids against C. albicans (A), S. aureus 
(B) and E. coli (C) monospecies biofilms determined by crystal violet assay. 
Biofilms were treated with peptoids (100 µM) and compared with untreated, 
control biofilms. The results (average of 3 independent experiments) were 
plotted as percent biomass of controls. Statistical analysis was determined by 
one-way ANOVA followed by Tukey’s post hoc correction for multiple 
comparisons (ns: p > 0.05; *: p < 0.05; **: p < 0.01; ***: p < 0.001; ****: p < 
0.0001). 
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Table 1. Peptoid library synthesised on solid phase using the sub-monomer method: i. acylation step (bromoacetic acid and DIC in DMF, 15 mins, 50 ˚C); ii. 
displacement step (primary amine in DMF, 15 mins, 50 ˚C). Peptoids were split into 3 families (peptoids 1-6; peptoids 7-12 and peptoids 13-18) on the basis of 
their building blocks. 
 
   
Peptoid Sequence Nx Ny 
1 (NLysNpheNphe)4 
 
 
2 (NLysNpheNphe)3 
3 (NLysNpheNphe)2 
4 (NLysNspeNspe)4 
 
5 (NLysNspeNspe)3 
6 (NLysNspeNspe)2 
    
7 (NaeNpheNphe)4 
  
8 (NaeNpheNphe)3 
9 (NaeNpheNphe)2 
10 (NaeNspeNspe)4 
 
11 (NaeNspeNspe)3 
12 (NaeNspeNspe)2 
    
13 (NahNpheNphe)4 
 
 
14 (NahNpheNphe)3 
15 (NahNpheNphe)2 
16 
(NahNspeNspe)4 
 
17 
(NahNspeNspe)3 
18 
(NahNspeNspe)2 
The 18 peptoids tested had variable antifungal and antibacterial 
activities when screened for inhibitory activity against these 
single species biofilms Peptoids 5, 7 and 17 were amongst the 
most efficacious peptoids from each of the three peptoid families 
across all three single species biofilms studied.  
 
The peptoid library tested in this study contained peptoids of 
three different lengths: 6, 9 and 12 residue peptoid analogues. In 
agreement with previous studies24,30-31, the longest 12 residue 
peptoids tended to be most efficacious. The 12-mer peptoids 
were more active against C. albicans than 9 residue peptoids 
which had an intermediate activity and the 6 residue sequences 
were mostly inactive; for example, the comparison between 
peptoids 7 (12-mer), 8 (9-mer) and 9 (6-mer). For S. aureus, the 
longer 12-mer sequences also had good activity, but 
interestingly in most cases the comparable shorter 9 residue 
analogues caused a greater reduction in biofilm mass. As with C. 
albicans, the shortest 6 monomer peptoids were inactive.  For E. 
coli, the longest peptoids were the most active, except for those 
containing the Nah monomer, where the intermediate length 9 
residue peptoids were the most active (i.e. peptoids 13 and 17).  
Direct comparisons of sequence length effects with previously 
published literature28,29 are complicated by the differing side 
chains used and the resulting differences in charge: length ratios. 
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Figure 3. PMA-qPCR quantification of cell number following peptoid treatment of monospecies biofilms. Cell numbers of C. albicans (A), S. aureus (B) 
and E. coli (C) treated with 100 µM peptoids 5, 7 and 17 (****: p < 0.0001. One-way ANOVA followed by Tukey’s post hoc correction for multiple comparisons 
(average of 3 independent experiments). 
 
The success of many AMPs is attributed to their overall positive 
charge, which helps them to target prokaryotic cell membranes 
over mammalian cells16. Therefore, the effect of different cationic 
monomers was investigated across the peptoid library. When 
comparing peptoid sequences of the same overall length (i.e. 12 
residues), peptoids containing the shortest Nae monomer  
tended to be more active than the longer NLys monomer (e.g. 
compare peptoid 1 and peptoid 7) for all species. On the whole, 
peptoids containing the Nah monomer were less active than 
those containing either Nae or NLys30, although peptoid 17 is an 
exception. Potentially the reduced activity of the NahNyNy 
peptoids could stem from the greater flexibility of the longer 
aminohexane chain.  
 
The peptoid library was designed to include sequences 
containing either the chiral Nspe or the achiral Nphe monomer to 
determine the effect of sequence chirality on the anti-biofilm 
activities of the compounds. Therefore, a range of chiral and 
achiral peptoid analogues were tested. Overall, sequences 
containing Nspe were more efficacious than their achiral 
analogues (e.g. compare achiral peptoid 1 and chiral peptoid 4) 
across all three biofilm species tested. However, for peptoids 
containing the shortest Nae monomer, there was little difference 
in activity between the chiral and achiral peptoids (i.e. peptoids 
10-12 and 7-9 respectively) against S. aureus or C. albicans. 
The differences in activity for chiral and achiral members of the 
entire peptoid library were even less pronounced against E. coli. 
 
The entire peptoid library was also screened against two 
representative mammalian cell lines, HaCaT and HepG2, to 
determine if the sequences were selective for the bacteria and 
fungi tested (data provided in Supplementary Material). The 
majority of the peptoids had ED50 values > 100 μM against both, 
indicating that they had minimal cytotoxic effects on model 
human endothelial and keratinocyte cell lines. The only 
sequences that showed toxicity were the longest 12 residue 
peptoids containing the chiral Nspe monomer, peptoids 4, 10 
and 16. 
 
Although it is generally acknowledged that peptoids are 
inherently resistant towards proteolysis23,33, we compared the 
tryptic digestion profile of one selected peptoid, peptoid 7, 
against the naturally occurring alpha helical peptide LL-37. 
Peptoid 7 showed no degradation following treatment with 
trypsin for 24 hours whereas LL-37 was completely degraded to 
peptide fragments during the same time period (see 
Supplementary Material). 
 
Peptoid efficacy against polymicrobial biofilms 
 
Although widely used in biofilm assays, the crystal violet assay 
detects both live and dead organisms, in addition to matrix 
components. In this study, we developed a novel PCR method 
to selectively and quantitatively determine fungicidal and 
bactericidal activity against both monospeices and polymicrobial 
biofilms.  
 
Conventional CFU assays have been reported to underestimate 
live cell numbers because they cannot quantify VBNC cells.34,35 
Furthermore, micro-organisms have been shown to enter the 
VBNC sate when exposed to antibiotic treatment.36 Therefore 
the use of non-cultivation-based assays to evaluate the efficacy 
of novel antimicrobials is particularly appealing for studying 
micro-organisms in biofilm form. 
 
PMA is a photo-reactive dye with a high affinity for DNA, with 
which it forms a covalent linkage upon exposure to intense 
visible light. The use of PMA allows qPCR quantification of DNA 
from living cells only, because PMA binds covalently to DNA 
which lacks the protection of the cell membrane in a viable 
micro-organism.27, Since PMA discriminates between live and 
dead cells on the basis of their membrane integrity37, its addition 
to the qPCR protocol is particularly suitable for quantifying the 
efficacy of membrane-targeting agents such as peptoids. 
 
Three peptoids [5 (NLysNspeNspe)3, 7 (NaeNpheNphe)4, and 
17 (NahNspeNspe)3] were chosen for further study, as they 
represented some of the most active peptoids in the single 
species crystal violet assays and showed negligible toxicity to 
the two mammalian cell lines tested (see Supplementary 
Material). In addition all monospecies biofilms treated with these 
peptoids showed significant reduction in cell numbers, indicating 
strong bactericidal and fungicidal activity (Figure 3). The three 
peptoids had a similar efficacy against S. aureus, reducing cell   
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Figure 4. PMA-qPCR quantification of cell numbers following peptoid treatment of polymicrobial biofilms consisting of C. albicans and either S. aureus 
or E. coli. Cell numbers of C. albicans (A) and S. aureus (B) within the same polymicrobial biofilm, following treatment with 100 µM peptoids 5, 7 and 17. Cell 
numbers of C. albicans (C) and E. coli (D) within the same polymicrobial biofilm, following treatment with 100 µM peptoids 5, 7 and 17 (**: p < 0.01; ****: p < 
0.0001. One-way ANOVA followed by Tukey’s post hoc correction for multiple comparisons (average of 3 independent experiments). 
 
numbers by approximately two orders of magnitude, with 
peptoids 5 and 7 showing even better effects (reduction in cell 
number by over 4 orders of magnitude against this 
microorganism). In agreement with the crystal violet assay 
results, the Nah containing peptoid 17 did not perform quite as 
well against C. albicans, although it still caused a significant 
reduction in the fungal biofilm. Conversely, in the E. coli 
monospecies biofilms, peptoid 17 was the most effective. 
 
Peptoids 5, 7 and 17 were also tested against mixed species 
biofilms containing C. albicans and either S. aureus or E. coli. 
(Figure 4 shows treatment at 100 µM). At this treatment 
concentration the mixed species biofilm containing C. albicans 
and E. coli, the biofilm cell numbers were reduced more for C. 
albicans than for E. coli. In this particular polymicrobial biofilm, 
the Nah containing peptoid (17) was the most active. In the 
mixed species biofilm containing C. albicans and S. aureus, cell 
numbers were reduced more for bacteria than the fungi. Peptoid 
5 was better able to reduce the cell count of S. aureus when the 
biofilm was treated at 100 µM and peptoid 7 showed the 
greatest reduction in C. albicans. It was noted that C. albicans 
appeared to be less susceptible to peptoid 17 when it was 
present in a biofilm with S. aureus, but this did not appear to be 
the case in the presence of E. coli.  Since there has been very 
limited work on peptoid efficacy in polymicrobial biofilms it 
remains to be determined if this is a unique phenomenon. 
 
To look in more detail at the activity of peptoids 5, 7 and 17 
cross-kingdom biofilms were treated with these compounds at 
concentrations ranging from 10 – 100 µM (PMA-qPCR method 
used to determine cell viability as before – see details in 
Supplementary Information). In the mixed species biofilms 
investigated, all three peptoids (5, 7 and 17) were found to 
significantly reduced the cell numbers of S. aureus by 
approximately 100%, even when treated at 10 µM. Reduction in 
cell viability for E. coli or C. albicans was less efficacious at 10 
µM, but considerable reductions in cell numbers were seen at 25 
µM and 50 µM. For all three species present in the cross-
kingdom biofilms (i.e. C. albicans, S. aureus or E. coli), peptoid 
17 showed the greatest reduction in cell numbers. 
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Figure 5. Propensity for peptoids 5, 7 and 17 to permeabilise the microbial membranes of (a) C. albicans, (b) E. coli and (c) S. aureus, as determined by 
the SYTOX Green assay. The efficacy of membrane permeabilisation by peptoids was compared with untreated controls and the results (average of 3 
independent experiments) were analysed by ANOVA followed by Tukey’s post hoc correction for multiple comparisons (****: p < 0.0001). Cells permeabilised by 
heat treatment were used as positive controls. 
 
Effect of peptoids on microbial cell membranes  
 
The majority of linear antimicrobial peptides (AMPs) have been 
shown to exert their antimicrobial effects via disruption of 
pathogen cellular membranes. It is thought that as linear 
antimicrobial peptoids (such as those studied herein) are 
structurally very similar to this class of AMP that they may also 
exert their biological mode of action via cell membrane 
disruption. However, at present there are only a few studies 
reported in the literature that provide experimental evidence to 
support this hypothesis.38-42  
 
To help elucidate the mode of action of the peptoids studied in 
the qPCR experiments and to verify the use of the PMA-qPCR 
assay (PMA depends upon the integrity of the cell membrane), a 
membrane permeabilisation assay was performed with peptoids 
5, 7 and 17 at 100 µM against C. albicans, S. aureus and E. coli. 
The assay carried out uses the dye, SYTOX® Green, which is 
able to bind nucleic acids but is impermeable to living eukaryotic 
and prokaryotic cells. Therefore, this dye is routinely used to 
assess the integrity of cell membranes. If a microbial cell 
membrane has been compromised, for example by treatment 
with a peptoid, SYTOX® Green can bind to the cellular nucleic 
acids. This association event increases the fluorescence of the 
dye and renders cells with compromised membranes as brightly 
green fluorescent.43,44 
 
The propensity for the peptoids (5, 7 and 17) to permeabilise cell 
membranes was assessed using SYTOX® Green (Figure 5). The 
data obtained clearly showed that upon peptoid treatment a 
large increase in fluorescence was recorded signifying that all of 
the peptoids assayed caused cell membrane permeabilisation in 
C. albicans (Figure 5A), E. coli (Figure 5B) and S. aureus 
(Figure 5C).  
 
The results show that the peptoids that have the greatest 
antimicrobial effect against single species biofilms (Figure 3) 
also cause the greatest membrane permeabilisation via the 
SYTOX® Green assay (Figure 5). For example, against 
C. albicans peptoid 5 causes the greatest reduction in cell 
number and causes the greatest increase in fluorescence. The 
aforementioned results strongly support that the microbial action 
of peptoids 5, 7 and 17 is due to membrane disruption, but 
additional action via a secondary intracellular target cannot be 
completely ruled out. 
  
Conclusions 
In conclusion, peptoids, an emerging class of peptidomimetics 
that have previously been tested principally for their activity 
against bacteria in planktonic and biofilm form26,28,29,45,46 were 
shown for the first time, to be efficacious against C. albicans  
biofilms and against cross-kingdom polymicrobial biofilms. We 
have shown the in vitro effectiveness of a peptoid library against 
both single species C. albicans, S. aureus and E. coli biofilms 
and we also report their excellent fungicidal and bactericidal 
activity in polymicrobial biofilms using PMA-modified qPCR. In 
addition SYTOX® Green membrane leakage assays carried out 
identified that the cell membranes of C. albicans, S. aureus and 
E. coli are the likely targets through which the peptoids screened 
exert their antimicrobial mode of action.  
 
The peptoid library studied showed similar activity patterns 
across the three species tested by crystal violet assay, i.e. 
peptoids that were active at some level against one species also 
tended to be active against the others. However, it was noted 
that these peptoids generally caused the greatest reduction in 
biofilm mass against S. aureus, followed by C. albicans, with E. 
coli biofilms showing the least reduction in biofilm mass following 
peptoid treatment. Planktonic E. coli has also proven more 
difficult to treat than Gram positive bacteria in previous studies 
on peptoid efficacy.24, 25 
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From the qPCR data peptoid 17 (NahNspeNspe)3 was identified 
as the most promising candidate within the library. This peptoid 
has low toxicity, significant activity against S. aureus in a mixed 
species biofilm with C. albicans at 10 µM and it also shows good 
activity against both species within the C. albicans and E. coli 
cross-kingdom biofilm when treated at higher concentrations. 
 
Finally, peptoids potentially have an advantage over 
conventional antifungals and antibacterials in that their proposed 
biological mode of action, through the disruption of cellular 
membranes, limits the emergence of resistance and would 
require the targeted fungi and bacteria to undertake the arduous 
task of altering cellular membrane composition. Furthermore, 
their enhanced stability towards proteolytic degradation means 
that peptoids, rather than peptides, may represent a more 
realistic class of molecule for the development of new 
therapeutics. 
Experimental Section 
Peptoid synthesis  
Detailed synthesis procedure can be found in the Supplementary 
Information. Fmoc-protected Rink Amide resin (normally 100 mg, 0.1 
mmol, typical loading between 0.6–0.8 mmol g-1) was swollen in DMF (at 
least 1 hour at room temperature, overnight preferred) in a 20 mL 
polypropylene syringe fitted with two polyethylene frits (Crawford 
Scientific). The resin was deprotected with piperidine (20% in DMF v/v, 2 
x 20 min) and washed with DMF (3 x 2mL). The resin was treated with 
bromoacetic acid (8 eq. with respect to the resin, 2M in DMF) and DIC (8 
eq., 2M in DMF) for 15 minutes at 50 ˚C on a heated shaker at 400 rpm. 
The resin was washed with DMF (3 x 2 mL), before the desired amine 
sub-monomer was added (4 eq., 1M in DMF) and allowed to react for 15 
minutes at 50 ˚C on the shaker. The resin was again washed with DMF 
(3 x 2 mL) and the bromoacetylation and amine displacement steps were 
repeated until the final sub-monomer had been added and the desired 
peptoid sequence had been obtained. The resin was shrunk in diethyl 
ether (3 mL) and final cleavage from resin was achieved using  a TFA 
cleavage cocktail (4 mL, TFA:TIPS:H2O, 95:2.5:2.5) on the shaker at 400 
rpm for 60 minutes. The resin was removed by filtration and the cleavage 
cocktail removed in vacuo. The crude product was precipitated in diethyl 
ether (30 mL) and the precipitate retrieved by centrifuge for 15 min at 
5,000 rpm. The ether phase was decanted and the crude product 
dissolved in a mixture of acidified H2O and MeCN and lyophilised before 
purification by RP-HPLC and subsequent characterisation (see 
Supplementary Information for equipment, procedures and data). 
Peptoid cytotoxicity studies  
All 18 peptoids were tested for their potential cytotoxicity against Hep G2 
epithelial and HaCaT keratinocyte cell lines. Cytotoxicity analyses were 
performed in 96-well plates (Costar, Fisher Scientific) using alamarBlue® 
(Invitrogen) for cell viability detection as described by the manufacturer. 
The HepG2 cells were grown at 37 °C, 5% CO2 in DMEM high glucose 
supplemented with heat-inactivated foetal bovine sera (FBS, 10%; 
Biosera Ltd) and penicillin/streptomycin (P/S, 1%). HaCaT cells were 
subcultured at 37 °C, 5% CO2 in DMEM high glucose supplemented with 
heat-inactivated foetal bovine sera (FBS, 10%; Biosera Ltd) and 
penicillin/streptomycin (P/S, 1%). Cells were counted using a Neubauer 
Improved Haemocytometer. HepG2 or HaCaT cells were seeded 24 
hours prior to treatment in 96 well plates at a concentration of 2x105 
cells/mL in 100 µL of medium (2x104 cells/well). After 24 hours, cells 
were incubated with the compounds in a dilution series in triplicate from 2 
– 100 µM (5 mM stock solutions in DMSO) in 50 µL of the media for 1 
hour. Afterwards, 40 µL were removed from each well before the addition 
of 90 µL of the media, followed by incubation for 24 hours at 37 °C, 5% 
CO2. Then, 10 µL of alamarBlue® (Invitrogen) was added to each well 
before incubation (2 hours for Hep G2 cells or 1 hour for HaCaT cells) 
prior to assessing cell viability using a fluorescent plate reader (Biotek; 
Ex 560 nm / Em 600 nm). All data was measured in triplicate on a 
minimum of two occasions to ensure a robust data set was collected. 
Proteolytic stability studies  
Peptoids are considered to be inherently stable to proteolysis23, however 
peptoid stability was confirmed by comparing the tryptic digestion profile 
of one selected, peptoid 7 with the naturally occurring host defence 
peptide, LL-37 (Innovagen AB, Lund, Sweden). Substrate stocks (5 
mg/ml) of Peptoid 7 and LL-37 were prepared and 7.5µL of each 
substrate stock was incubated with 5µl trypsin and 37.5µL of incubation 
buffer (50mM tris-HCl pH 7.8, containing 9 mM CaCl2). After 0 hours (for 
mass spectrometric verification prior to tryptic digestion) or 24 hours 
treatment with trypsin the reaction mixtures were acidified by addition of 
an equal volume (50µL) of 10% trifluroacetic acid to stop further enzyme 
activity. The resulting samples were air-dried and then reconstituted in 
50µl acetonitrile/water/TFA (40/59.5/0.5 %, v/v/v) and 1 µL was carefully 
placed onto a stainless steel MALDI target. Samples were covered 
immediately with 1 µl of matrix (53 mM α-cyano-4-hydroxycinnamic acid 
in acetonitrile/water/TFA, 70/29.98/0.02 %, v/v/v) solution. MALDI-TOF 
MS was performed using a linear time-of-flight Voyager DE-mass 
spectrometer (Perseptive Biosystems, UK). The samples were analysed 
in positive detection mode, and internal mass calibration with known 
standards established the mass accuracy as ±0.1 %. Fifty laser scans 
were averaged for each sample and variable laser intensities were used 
to ensure the most representative mass spectra for the wells were 
produced. 
Micro-organism strains and growth conditions 
C. albicans (NCTC 3179) was subcultured aerobically on Sabouraud 
agar plates and propagated in yeast peptone dextrose broth. E.coli 
(ATCC 29522) and S.aureus (NCTC 6571) were grown on blood agar 
plates and propagated in brain heart infusion (BHI) broth. 
Preparation and treatment of single species biofilms 
Overnight cultures of C. albicans were washed and resuspended in a 
modified RPMI-1640 (Sigma-Aldrich, St Louis, USA) medium to yield an 
inoculum of 1.0 × 106 cells/mL. Overnight cultures of S. aureus or E. coli 
were washed and resuspended in brain heart infusion broth (Oxoid, 
Basingstoke, UK) to yield an inoculum of 5.0 × 106 cells/mL. A total 
volume of 100 µL of each inoculum was added to microtitre plate wells 
(Thermo Fisher Scientific, Roskilde, Denmark). An initial biofilm was 
allowed to form for 4 hours. Wells were washed three times with 200 µL 
PBS to facilitate removal of planktonic cells and the biofilms were then 
treated with 100 µM of peptoids 1-18 in the appropriate broth. Plates 
were incubated for a further 24 hours to allow biofilm maturation. After 
removal of planktonic cells by washing, biofilms were quantified by the 
crystal violet assay or by PMA-qPCR.  
Preparation and treatment of polymicrobial biofilms 
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Overnight cultures of C. albicans were prepared in microtitre plates as 
outlined above and allowed to adhere for 4hrs to facilitate initial biofilm 
formation. Planktonic C. albicans cells were then removed as outlined 
above before the addition of 100µl of S. aureus or E. coli (5.0 × 106 
cells/mL). Bacteria were allowed to adhere to the C. albicans biofilms for 
4hrs to facilitate polymicrobial biofilm formation. Following a washing step, 
the biofilms were then treated with peptoids (10-100 µM), and incubated 
for a further 24 hours to allow biofilm maturation. Wells were washed as 
previously outlined and the polymicrobial biofilms were quantified by 
PMA-modified qPCR. 
Biofilm quantification by crystal violet assay 
Washed biofilms were fixed with 100 µl methanol for 10 minutes. 
Following removal of methanol, the wells were air dried and stained with 
crystal violet solution (Clin-Tech Ltd, Guildford, UK) for 20 minutes at 
room temperature. Excess stain was removed by washing, the plate was 
then air dried and bound crystal violet was re-solubilised in 160 μL 33% 
acetic acid prior to reading at 57 0nm in a microtitre plate reader (Tecan 
GENios, Zürich, Switzerland).  
Biofilm quantification by PMA-modified qPCR 
To determine the bactericidal and fungicidal activity of peptoids against 
both single species and polymicrobial biofilms, the biofilms were 
detached from the microtitre plate wells prior to quantification. Wells were 
washed as previously described before 100 μL of BHI broth was added 
and the plate was sealed. Biofilm detachment was achieved by 
sonication for 5mins in an ultrasonic bath (Dawe, Middlesex, UK). The 
remaining cells were then collected in 80 μL BHI. Twenty μL of PMA 
(Biotium Inc., California, USA) (2mM in broth47) was added to the biofilm 
suspensions (180μl) and incubated at 37°C (5 min) prior to 
photoactivation with a broad-spectrum LED flood light placed at 15cm 
from the tubes, (which were mixed by inversion during the 20min 
photoactivation step)48. DNA was extracted using the microLYSIS®-Plus 
kit (Microzone, Haywards Heath, UK) as per the manufacturer’s 
instructions and qPCR was performed in a Mx3005P qPCR System 
(Agilent Technologies, California USA) as detailed in Supplementary 
tables.49-51 
Generation of standard curves for PMA-qPCR 
To allow quantification of the numbers of C. albicans, S. aureus and E. 
coli within both single species and polymicrobial biofilms, DNA standards 
were prepared by extraction of DNA from planktonic organisms using the 
microLYSIS®-Plus kit and purified using the DNeasy kit (Qiagen, 
Manchester, UK). DNA standards corresponding to cell numbers from 
101 to 106 were used in PMA-qPCR assays to generate standard curves 
from which the numbers of living organisms within the biofilms could be 
determined. 
SYTOX® Green assay 
Briefly, mid log phase microorganism cultures were adjusted to the 
appropriate concentration (OD 0.7 at 600nm for S. aureus and E. coli, 
OD 2.0 at 600nm for C. albicans). A 50 µL of microorganism suspension 
in Mueller Hinton broth (MHB) was added to each well of a 96 well black 
flat bottomed plate. 50 µL of each peptoid to be tested at final 
concentration of 100 µM were added to the wells. SYTOX® Green was 
added to each well to a final concentration of 5 µM. The plate was 
covered, protected from light and incubated for 2 hours at 37 ˚C. 
Microorganisms which had been heat treated at 99 ˚C for 10 minutes to 
permeabilise their membranes served as positive controls. Bacteria 
without any form of peptoid treatment acted as negative controls. 
Additional control wells containing SYTOX® Green only were included to 
ensure there was no background fluorescence. Wells containing 
SYTOX® Green and peptoid only were included to ensure there were no 
interactions between the SYTOX® Green and peptoids that could lead to 
non-specific fluorescence measurements. The plate was read on a 
fluorimeter (SpectraMax Gemini X fluorimeter; λex 480 nm, λem 530 nm). 
Statistical analysis 
The susceptibility of C. albicans, S.aureus and E.coli in both single 
species and polymicrobial biofilms to novel peptoids was determined by 
biofilm inhibition assays. All data represent an average of 3 independent 
experiments and were subject to statistical analysis by One-way ANOVA 
followed by Tukey’s post hoc correction for multiple comparisons, where 
ns: p>0.5; * p< 0.5; **p<0.05, ***p< 0.001; **** p< 0.0001.  
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